Glaucoma Eye Drops Market, by Drug Type (Prostaglandin analogs, Beta blockers, Alpha agonists, Carbonic Anhydrase Inhibitors (CAIs), Combined Medications and Others (rho-kinase inhibitor, Cholinergic agonist)), by Disease Indication (Angle-closure Glaucom

Glaucoma Eye Drops Market, by Drug Type (Prostaglandin analogs, Beta blockers, Alpha agonists, Carbonic Anhydrase Inhibitors (CAIs), Combined Medications and Others (rho-kinase inhibitor, Cholinergic agonist)), by Disease Indication (Angle-closure Glaucoma and Open-angle Glaucoma), By Distribution Channel (Hospital Pharmacy Retail Pharmacy and Online Pharmacy), by Composition (Preservative Free, BAK-Based and Non BAK-Based Preservatives ), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Glaucoma may occur among the people with or without diabetes. Moreover, people with diabetic retinopathy have an increased risk of glaucoma. The condition is associated with abnormal blood vessel growth, which can result in retinopathy and leads to blockage of natural drainage of the eye. Rapidly increasing geriatric population is one of the important factors for increasing prevalence of glaucoma, which in turn is projected to drive growth of the glaucoma therapeutics market in near future. For instance, according to the International Diabetes Foundation (IDF) 2017 statistics, the number of people with diabetes aged between 20 to 79 years are increasing worldwide.
Market Dynamics
The global glaucoma eye drops market is expected to witness significant growth during the forecast period owing to the increasing prevalence of glaucoma, For instance, according to the International Agency for the Prevention of Blindness, in 2015, an estimated 3 million people suffered from blindness due to glaucoma in the U.S. Furthermore, as per the same source, it is estimated that by 2020 around 80 million people will suffer from glaucoma, with an increase of about 20 million from 2010 globally.
Key features of the study:
This report provides in-depth analysis of the global glaucoma eye drops market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global glaucoma eye drops market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Merck & Co., Inc., Allergan Plc., Novartis AG., Teva Pharmaceutical Industry, Pfizer, Inc., Bausch & Lomb Inc., Inotek Pharmaceutical, Jadran-galenski laboratorij d.d., Aerie Pharmaceutical, and Mylan N.V.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, government initiatives, technological upgradation, market expansion, and marketing tactics
The global glaucoma eye drops market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for glaucoma eye drops, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:
Global Glaucoma Eye Drops Market, By Drug Type:
Prostaglandin analogs
Beta blockers
Alpha agonists
Carbonic Anhydrase Inhibitors (CAIs)
Combined Medications
Others (rho-kinase inhibitor, Cholinergic agonist)
Global Glaucoma Eye Drops Market, By Disease Indication:
Angle-closure Glaucoma
Open-angle Glaucoma
Global Glaucoma Eye Drops Market, By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global Glaucoma Eye Drops Market, By Composition:
Preservative Free
BAK-Based
Non BAK-Based Preservatives
Global Glaucoma Eye Drops Market, By Region:
North America
By Country:
U.S.
Canada
By Drug Type:
Prostaglandin analogs
Beta blockers
Alpha agonists
Carbonic Anhydrase Inhibitors (CAIs)
Combined Medications
Others (rho-kinase inhibitor, Cholinergic agonist)
By Disease Indication:
Angle-closure Glaucoma
Open-angle Glaucoma
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Composition:
Preservative Free
BAK-Based
Non BAK-Based Preservatives
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Type:
Prostaglandin analogs
Beta blockers
Alpha agonists
Carbonic Anhydrase Inhibitors (CAIs)
Combined Medications
Others (rho-kinase inhibitor, Cholinergic agonist)
By Disease Indication:
Angle-closure Glaucoma
Open-angle Glaucoma
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Composition:
Preservative Free
BAK-Based
Non BAK-Based Preservatives
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Type:
Prostaglandin analogs
Beta blockers
Alpha agonists
Carbonic Anhydrase Inhibitors (CAIs)
Combined Medications
Others (rho-kinase inhibitor, Cholinergic agonist)
By Disease Indication:
Angle-closure Glaucoma
Open-angle Glaucoma
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Composition:
Preservative Free
BAK-Based
Non BAK-Based Preservatives
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Type:
Prostaglandin analogs
Beta blockers
Alpha agonists
Carbonic Anhydrase Inhibitors (CAIs)
Combined Medications
Others (rho-kinase inhibitor, Cholinergic agonist)
By Disease Indication:
Angle-closure Glaucoma
Open-angle Glaucoma
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Composition:
Preservative Free
BAK-Based
Non BAK-Based Preservatives
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drug Type:
Prostaglandin analogs
Beta blockers
Alpha agonists
Carbonic Anhydrase Inhibitors (CAIs)
Combined Medications
Others (rho-kinase inhibitor, Cholinergic agonist)
By Disease Indication:
Angle-closure Glaucoma
Open-angle Glaucoma
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Composition:
Preservative Free
BAK-Based
Non BAK-Based Preservatives
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Drug Type:
Prostaglandin analogs
Beta blockers
Alpha agonists
Carbonic Anhydrase Inhibitors (CAIs)
Combined Medications
Others (rho-kinase inhibitor, Cholinergic agonist)
By Disease Indication:
Angle-closure Glaucoma
Open-angle Glaucoma
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Composition:
Preservative Free
BAK-Based
Non BAK-Based Preservatives
Company Profiles
Merck & Co., Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Allergan Plc.
Novartis AG
Teva Pharmaceutical Industry
Pfizer, Inc.
Bausch & Lomb Inc.
Inotek Pharmaceutical
Jadran-galenski laboratorij d.d.
Aerie Pharmaceutical
Mylan N.V

“*” marked represents similar segmentation in other categories in the respective section.